Coronavirus disease treatment pill Paxlovid is seen in a box, at Misericordia hospital in Grosseto, Italy, February 8, 2022.
The National Medical Products Administration said Paxlovid is approved to treat adults who have mild to moderate COVID-19 and high risk of progressing to a severe condition. Further study on the drug needed to be conducted and submitted to the authority, it said.“This is an important milestone in our fight against COVID-19,” a Pfizer representative said in a statement, without providing information about procurement.
Pfizer in December said final trial results showed its treatment reduced the chance of hospitalisation or death by 89% in COVID-19 patients at risk of severe illness given the treatment within three days of the onset of symptoms, and by 88% when given within five days of onset. China has kept a daily number of new COVID-19 patients with confirmed symptoms to below 250 and sometimes fewer than 10, in the past year.
still in China 🇨🇳🇨🇳.. ... I'm still not interested about vaccines PASS PORT 🥂🥂🥂🇿🇦🇿🇦🇿🇦🇿🇦